Speciality: Cardiology
Description:
.A warm welcome to all the medical professionals in this interesting live Session on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) by Pfizer.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a progressive and often underdiagnosed condition characterized by the deposition of abnormal transthyretin protein in the heart tissue. Pfizer, a leading pharmaceutical company, is at the forefront of research and development in the field of ATTR-CM.
Through innovative therapies and groundbreaking clinical trials, Pfizer aims to improve the diagnosis, management, and outcomes for patients affected by this debilitating disease. With a commitment to advancing medical science and enhancing patient care, Pfizer's efforts in the field of ATTR-CM offer hope for those living with this challenging condition.
Therefore, get an overall knowledge on detecting fetal aneuploidies in maternal blood. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions
See More Webinars @ Hidoc Webinars
1.
Adult overdose deaths on the rise
2.
What Role Should Genomic Classifier Testing Play in Prostate Cancer?
3.
To automate the biopharmaceutical facilities of Reliance Life Sciences, ABB India has won the contract.
4.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
5.
New study links air pollution with higher rates of head and neck cancer
1.
Liquid Biopsy in Oncology: Innovations in Cancer Detection, Monitoring, and Clinical Use
2.
Essential Oncology Tools: Risk Assessment, Telehealth, AI, and Monitoring
3.
The Importance of Maintaining Normal Calcium Levels in Your Body
4.
The Truth About Marijuana and Its Effect on Mental Health
5.
Mastering Modern Oncology: Accreditation, Education, and Research Trends for 2025
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part II
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
5.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation